CLAIMS

1. Immediate release, oral pharmaceutical formulation comprising, ~~wherein it comprises:~~
- from ~~15~~ 18 to 30% by weight of nalbuphine or a pharmaceutically acceptable salt thereof, and from;
- from ~~50~~ 55 to 70% by weight of at least one ~~an~~ hydrophilic granulation carrier;
- from ~~2~~ 4 to 10% by weight of at least one ~~an~~ hydrophilic binder; and
- from ~~1~~ 2 to ~~5~~7% by weight of at least one lubricant, relative to the total weight of the formulation, said immediate release, oral pharmaceutical formulation only containing nalbuphine or one of the pharmaceutically acceptable salts thereof as an active ingredient.

2. The pharmaceutical formulation according to claim 1, wherein it comprises:
- from 18 to 22% by weight of nalbuphine;
- from 55 to 65% by weight of an hydrophilic granulation carrier;
- from 4 to 8% by weight of an hydrophilic binder; and
- from 2 to 3% by weight of at least one lubricant.

3. The pharmaceutical formulation according to claim 1 or 2 wherein the nalbuphine is under the form of its hydrochloride.

4. The pharmaceutical formulation according to any of claims 1 to 3, wherein the the hydrophilic granulation carrier is selected from the group comprising mannitol, polyvinyl pyrrolidone or a derivative thereof, a polyol, lactose, a cellulose derivative, polyethylene glycol or a derivative thereof and a silica derivative.

5. The pharmaceutical formulation according to any of claims 1 to 4, wherein the hydrophilic binder is selected from the group comprising polyvinyl pyrrolidone or a derivative thereof, a polyol, lactose, a cellulose derivative, polyethylene glycol or a derivative thereof, gums and carbomers.

6. The pharmaceutical formulation according to any of claims 1 to 5, wherein the lubricant is selected from the group comprising silicon dioxide, magnesium stearate, anhydrous colloidal silica, sodium stearyl fumarate and talcum.

7. The pharmaceutical formulation according to any of claims 1 to 6, wherein it further comprises:
- at least one disintegrating agent; and optionally
- at least one excipient.

8. A pharmaceutical formulation, wherein it comprises:
- from ~~15~~ 18 to 30% by weight of nalbuphine;
- from ~~50~~ 55 to 70% by weight of lactose;
- from ~~2~~ 4 to 10% by weight of PVP; and
- from ~~1~~ 2 to ~~5~~7% by weight of at least one lubricant.

9. The pharmaceutical formulation according to any of claims 1 to 8, wherein it is in solid form.